$0.00
0.00%
Nasdaq, Mon, Sep 02 2024
ISIN
CH0346177709
Symbol
OBSV
Sector
Industry

ObsEva SA Stock price

$0.00
+0.00 0.00% 1M
-0.01 99.20% 6M
-0.03 99.71% YTD
-0.07 99.86% 1Y
-3.19 100.00% 3Y
-9.52 100.00% 5Y
-11.65 100.00% 10Y
Nasdaq, Closing price Mon, Sep 02 2024
+0.00 0.00%
ISIN
CH0346177709
Symbol
OBSV
Sector
Industry

Key metrics

Market capitalization $0.00
Enterprise Value $-2.58m
P/E (TTM) P/E ratio 0.00
P/B ratio (TTM) P/B ratio 0.00
EBIT (operating result TTM) EBIT $-15.80m
Short interest 0.78%

Is ObsEva SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

ObsEva SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ObsEva SA forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a ObsEva SA forecast:

Hold
100%

Financial data from ObsEva SA

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '23
+/-
%
- -
-
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -16 -16
75% 75%
-
Net Profit - -
-
-

In millions USD.

Don't miss a Thing! We will send you all news about ObsEva SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ObsEva SA Stock News

Neutral
GlobeNewsWire
5 months ago
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH126004193...
Neutral
GlobeNewsWire
6 months ago
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that, concurrent to the decision to wind-down the company's operations, Catarina Edfjäll, Ph.D.
Neutral
GlobeNewsWire
6 months ago
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority...
More ObsEva SA News

Company Profile

ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.

Head office Switzerland
CEO Fabien Ladonchamps
Employees 15
Founded 2012
Website www.obseva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today